{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:43:09Z","timestamp":1790660589666,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Liaoning Chengda Biological Limited by Share Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-88361-1","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:55:30Z","timestamp":1740747330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens"],"prefix":"10.1038","volume":"15","author":[{"given":"Hua-Kun","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Song","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Gang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zhen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"88361_CR1","unstructured":"Rabies Preprint at https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies."},{"key":"88361_CR2","doi-asserted-by":"publisher","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","volume":"3","author":"AR Fooks","year":"2017","unstructured":"Fooks, A. R. et al. Rabies. Nat. Reviews Disease Primers. 3, 17091 (2017).","journal-title":"Nat. Reviews Disease Primers"},{"key":"88361_CR3","first-page":"569","volume":"37","author":"AC Jackson","year":"2018","unstructured":"Jackson, A. C. Rabies: a medical perspective. Revue Scientifique Et Technique (International Office Epizootics). 37, 569\u2013580 (2018).","journal-title":"Revue Scientifique Et Technique (International Office Epizootics)"},{"key":"88361_CR4","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1016\/j.vaccine.2010.08.082","volume":"28","author":"Rabies vaccines","year":"2010","unstructured":"Rabies vaccines. WHO position paper\u2014recommendations. Vaccine 28, 7140\u20137142 (2010).","journal-title":"Vaccine"},{"key":"88361_CR5","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.4161\/21645515.2014.972773","volume":"10","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults. Hum. Vaccines Immunotherapeutics. 10, 2805\u20132812 (2014).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR6","first-page":"1311","volume":"11","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Double-blind, controlled phase III clinical trial to evaluate the immunogenicity and safety of a lyophilized human rabies vaccine (vero cells) in healthy participants aged 10\u201360 years following Essen and Zagreb vaccination procedures. Nato Adv. Sci. Inst. Se. 11, 1311 (2023). A Randomized.","journal-title":"Nato Adv. Sci. Inst. Se"},{"key":"88361_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4161\/21645515.2014.995059","volume":"11","author":"B Mahendra","year":"2015","unstructured":"Mahendra, B. et al. Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen). Hum. Vaccines Immunotherapeutics. 11, 428\u2013434 (2015).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4161\/21645515.2014.994460","volume":"11","author":"R Li","year":"2015","unstructured":"Li, R. et al. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study. Hum. Vaccines Immunotherapeutics. 11, 435\u2013442 (2015).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1080\/21645515.2016.1230260","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above. Hum. Vaccines Immunotherapeutics. 13, 144\u2013150 (2017).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2217\/cer-2019-0202","volume":"9","author":"T Li","year":"2020","unstructured":"Li, T., Wang, X. & Cheng, H. Meta-analysis of immunogenicity and safety of human rabies vaccination under Zagreb and Essen regimens. J. Comp. Eff. Res. 9, 459\u2013468 (2020).","journal-title":"J. Comp. Eff. Res."},{"key":"88361_CR11","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/j.vaccine.2022.06.035","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: a systematic review and meta-analysis. Vaccine 40, 4371\u20134379 (2022).","journal-title":"Vaccine"},{"key":"88361_CR12","unstructured":"Rabies Vaccine Information Statement | CDC. Preprint at https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/rabies.html (2023)."},{"key":"88361_CR13","unstructured":"Rabies post-exposure treatment. management guidelines. GOV.UK Preprint at https:\/\/www.gov.uk\/government\/publications\/rabies-post-exposure-prophylaxis-management-guidelines (2023)."},{"key":"88361_CR14","unstructured":"Canada, P. H. A. of. Rabies vaccines: Canadian Immunization Guide. Preprint at https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-18-rabies-vaccine.html (2023)."},{"key":"88361_CR15","unstructured":"Circular on the issuance of the Code of Practice for the Prevention and Disposal of Rabies Exposure. Preprint at https:\/\/www.ndcpa.gov.cn\/jbkzzx\/c100012\/common\/content\/content_1706568784078565376.html (2023)."},{"key":"88361_CR16","unstructured":"QSMI Guideline for Pos-Exposure Rabies Treatment. Preprint at http:\/\/www.ppho.go.th\/webppho\/dl_strat\/F20180507090343.pdf."},{"key":"88361_CR17","unstructured":"Rabies Prevention and Control Program | Department of Health website. Preprint at https:\/\/doh.gov.ph\/national-rabies-prevention-and-control-program."},{"key":"88361_CR18","doi-asserted-by":"publisher","first-page":"A88","DOI":"10.1016\/j.vaccine.2018.10.103","volume":"37","author":"A Tarantola","year":"2019","unstructured":"Tarantola, A., Tejiokem, M. C. & Briggs, D. J. Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines. Vaccine 37, A88\u2013A93 (2019).","journal-title":"Vaccine"},{"key":"88361_CR19","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1080\/21645515.2021.1906601","volume":"17","author":"J Hu","year":"2021","unstructured":"Hu, J. et al. Long-term immunity and the effect of one or two booster doses with a lyophilized human rabies vaccine (human diploid cells) at 10 years post primary vaccination in China. Hum. Vaccines Immunotherapeutics. 17, 3162\u20133168 (2021).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR20","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/v14112458","volume":"14","author":"J Kim","year":"2022","unstructured":"Kim, J. et al. Effect of previous COVID-19 vaccination on humoral immunity 3 months after SARS-CoV-2 omicron infection and booster effect of a fourth COVID-19 vaccination 2 months after SARS-CoV-2 omicron infection. Viruses 14, 2458 (2022).","journal-title":"Viruses"},{"key":"88361_CR21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"APS Munro","year":"2022","unstructured":"Munro, A. P. S. et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect. Dis. 22, 1131\u20131141 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"88361_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0264-410X(97)00207-7","volume":"15","author":"R Vodopija","year":"1997","unstructured":"Vodopija, R. et al. Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. Vaccine 15, 571\u2013574 (1997).","journal-title":"Vaccine"},{"key":"88361_CR23","first-page":"254","volume":"16","author":"C Wang","year":"2010","unstructured":"Wang, C., Zhang, X. & Yu, Y. Study on the compliance and economic cost of rabies vaccination. Chin. J. Vaccines Immun. 16, 254\u2013257 (2010).","journal-title":"Chin. J. Vaccines Immun."},{"key":"88361_CR24","first-page":"607","volume":"23","author":"Z Huang","year":"2019","unstructured":"Huang, Z. et al. Persistence of rabies antibody 3 years after postexposure prophylaxis with 2-1-1 regimen of Vero-cell rabies vaccine for human use and antibody response to two booster doses. Chin. J. Disease Control Prev. 23, 607 (2019).","journal-title":"Chin. J. Disease Control Prev."},{"key":"88361_CR25","first-page":"74","volume":"28","author":"Z Huang","year":"2022","unstructured":"Huang, Z. et al. Immune persistence of primary vaccination and immunogenicity and safety of booster vaccination with human rabies vaccine (Vero cell) among 18\u201350 - year-old exposed individuals. Chin. J. Vaccines Immun. 28, 74\u201377 (2022).","journal-title":"Chin. J. Vaccines Immun."},{"key":"88361_CR26","doi-asserted-by":"publisher","first-page":"e3412","DOI":"10.1371\/journal.pntd.0003412","volume":"8","author":"Y Fang","year":"2014","unstructured":"Fang, Y. et al. Comparison of safety and immunogenicity of PVRV and PCECV immunized in patients with WHO category II animal exposure: a study based on different age groups. PLoS Negl. Trop. Dis. 8, e3412 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"88361_CR27","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1080\/21645515.2017.1279770","volume":"13","author":"N Shi","year":"2017","unstructured":"Shi, N. et al. Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects. Hum. Vaccines Immunotherapeutics. 13, 1338\u20131345 (2017).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR28","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1080\/21645515.2021.1880200","volume":"17","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: a post-marketing, parallel control clinical trial. Hum. Vaccines Immunotherapeutics. 17, 2547\u20132553 (2021).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR29","first-page":"233","volume":"32","author":"J Zhu","year":"2018","unstructured":"Zhu, J., Wu, X., Li, Y. H., Zhu, F. & Hu, Y. Investigation on the effects of booster immunization of human diploid cell rabies vaccine after eight years of primary vaccination. Chin. J. Clin. Hepatol. 32, 233\u2013236 (2018).","journal-title":"Chin. J. Clin. Hepatol."},{"key":"88361_CR30","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1016\/j.vaccine.2022.07.037","volume":"40","author":"BP Quiambao","year":"2022","unstructured":"Quiambao, B. P. et al. One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: a phase III, open-label, randomized, controlled trial to assess immunogenicity and safety. Vaccine 40, 5347\u20135355 (2022).","journal-title":"Vaccine"},{"key":"88361_CR31","first-page":"309","volume":"9","author":"P Parize","year":"2021","unstructured":"Parize, P. et al. Systematic booster after rabies pre-exposure prophylaxis to alleviate rabies antibody monitoring in individuals at risk of occupational exposure. Nato Adv. Sci. Inst. Se. 9, 309 (2021).","journal-title":"Nato Adv. Sci. Inst. Se"},{"key":"88361_CR32","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1016\/j.vaccine.2016.09.058","volume":"34","author":"KL Mansfield","year":"2016","unstructured":"Mansfield, K. L. et al. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans. Vaccine 34, 5959\u20135967 (2016).","journal-title":"Vaccine"},{"key":"88361_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/vbz.2019.2526","volume":"20","author":"G Dougas","year":"2020","unstructured":"Dougas, G. et al. Antibody response following pre-exposure immunization against rabies in high-risk professionals. Vector Borne Zoonotic Dis. (Larchmont N Y). 20, 303\u2013309 (2020).","journal-title":"Vector Borne Zoonotic Dis. (Larchmont N Y)"},{"key":"88361_CR34","doi-asserted-by":"publisher","first-page":"e0004920","DOI":"10.1371\/journal.pntd.0004920","volume":"10","author":"R Medeiros","year":"2016","unstructured":"Medeiros, R. et al. Persistence of rabies virus-neutralizing antibodies after vaccination of rural population following vampire bat rabies outbreak in Brazil. PLoS Negl. Trop. Dis. 10, e0004920 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"88361_CR35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.vaccine.2013.12.019","volume":"32","author":"N Banga","year":"2014","unstructured":"Banga, N., Guss, P., Banga, A. & Rosenman, K. D. Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. Vaccine 32, 979\u2013983 (2014).","journal-title":"Vaccine"},{"key":"88361_CR36","doi-asserted-by":"crossref","unstructured":"Brown, D., Fooks, A. R. & Schweiger, M. Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels. Adv. Prev. Med. 2011, e601789 (2011).","DOI":"10.4061\/2011\/601789"},{"key":"88361_CR37","doi-asserted-by":"publisher","first-page":"e5049","DOI":"10.1097\/MD.0000000000005049","volume":"95","author":"J Peng","year":"2016","unstructured":"Peng, J. et al. Safety comparison of four types of rabies vaccines in patients with WHO category II animal exposure: an observation based on different age groups. Med. (Baltim). 95, e5049 (2016).","journal-title":"Med. (Baltim)."},{"key":"88361_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4161\/hv.22377","volume":"9","author":"G Huang","year":"2013","unstructured":"Huang, G. et al. Safety of post-exposure rabies prophylaxis during pregnancy: a follow-up study from Guangzhou, China. Hum. Vaccines Immunotherapeutics. 9, 177\u2013183 (2013).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR39","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.4161\/21645515.2014.979621","volume":"10","author":"J Peng","year":"2014","unstructured":"Peng, J. et al. Effect of corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG. Hum. Vaccines Immunotherapeutics. 10, 3622\u20133626 (2014).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR40","first-page":"2666","volume":"14","author":"ZG Zhu","year":"2018","unstructured":"Zhu, Z. G., Zheng, Y., Lu, S., Hu, Q. & Fang, Y. Rabies post-exposure prophylaxis for a male with severe Henoch Sch\u00f6nlein purpura following rabies vaccination. Hum. Vaccines Immunotherapeutics. 14, 2666\u20132668 (2018).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"88361_CR41","unstructured":"WHO Expert Consultation on Rabies: WHO TRS N\u00b0982. Preprint at https:\/\/www.who.int\/publications-detail-redirect\/WHO-TRS-982."},{"key":"88361_CR42","unstructured":"Notice of the National Food and Drug Administration on Issuing the Guidelines for. the Classification of Adverse Events in Clinical Trials of Preventive Vaccines (No. 102 [2019]). Preprint at https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20191231111901460.html."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88361-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:55:40Z","timestamp":1740747340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88361-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88361"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88361-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial was approved by Institutional Review Board (IRB) of Zhejiang Provincial Center for Disease Control and Prevention (approval number: 2021-001-01), and adhered to the Good Clinical Practice (GCP), Declaration of Helsinki, and Chinese regulatory requirements. All participants and their guardians (for the participants aged 10\u201317 years) were fully informed before screening. Written informed consent was obtained from the participants (if aged 18\u201360 years) or the participants (if aged 10\u201317 years) and their guardians prior to study screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Miaomiao Liu, Yan Wang and Yu Mao are the employees of Liaoning Chengda Biological Limited by Share Ltd, the other authors had no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7079"}}